Zoetis Inc. (NYSE:ZTS) Shares Bought by IMS Capital Management

IMS Capital Management boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 11.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,958 shares of the company’s stock after acquiring an additional 300 shares during the quarter. IMS Capital Management’s holdings in Zoetis were worth $543,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Webster Bank N. A. grew its holdings in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares during the period. Quarry LP grew its position in Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in shares of Zoetis during the fourth quarter worth $40,000. LRI Investments LLC acquired a new stake in shares of Zoetis during the 1st quarter valued at about $43,000. Finally, Hazlett Burt & Watson Inc. lifted its stake in Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after acquiring an additional 102 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.3 %

Shares of NYSE ZTS opened at $195.38 on Tuesday. The business has a fifty day moving average of $186.33 and a two-hundred day moving average of $174.93. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92. The stock has a market cap of $88.52 billion, a PE ratio of 37.65, a PEG ratio of 2.99 and a beta of 0.88.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.41 earnings per share. As a group, equities research analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ZTS. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday, September 18th. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.